[The effect of thyrotrophin releasing hormone versus placebo in combination with basic imipramine therapy of depressive patients].
Otto Benkert, Lücke Kh
Abstract
Otto Benkert, Lücke Kh
Abstract
20 female and 10 male patients with a retarded-depressive syndrome received imipramine (3 X 50 mg/day) for 20 days. In a double blind study oral thyrotrophin releasing hormone (TRH) (2 X 40 mg/day) and placebo, respectively, were added for the first 2 weeks. The patients were rated with the Hamiltion-depression scale and a selfrating depression scale. But the statistical evaluation showed no difference between the imipramine/TRH and the imipramine/placebo group.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
20 female and 10 male patients with a retarded-depressive syndrome received imipramine (3 X 50 mg/day) for 20 days. In a double blind study oral thyrotrophin releasing hormone (TRH) (2 X 40 mg/day) and placebo, respectively, were added for the first 2 weeks. The patients were rated with the Hamiltion-depression scale and a selfrating depression scale. But the statistical evaluation showed no difference between the imipramine/TRH and the imipramine/placebo group.
Key concepts: Imipramine, Placebo, Depression (economics), Internal medicine, Medicine, Hormone, Placebo group, Endocrinology